Cadence Pharmaceuticals Inc (CADX) Return on Assets ROA from the fourth quarter of 2013 to fourth quarter of 2012 and for the year 2013, Average High and Low, Fundamental Ratios from Dec 31 2013 to Dec 31 2012 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Cadence Pharmaceuticals Inc  (CADX)


Cadence Pharmaceuticals Inc's ROA from the fourth quarter of 2013 to the fourth quarter of 2012 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Cadence Pharmaceuticals Inc's ROA in the fourth quarter of 2013?
Cadence Pharmaceuticals Inc achieved a return on average assets (ROA) of 36.75 % in its fourth quarter of 2013, this is above CADX's average return on assets of -70.89%.
Cadence Pharmaceuticals Inc assets over the 12 months ending in its fourth quarter of 2013 are valued at $184 million

ROA has improved compared to -54.37% in the third quarter of 2013, due to net income growth.

However, within the Healthcare sector 36 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Dec 31 2013 quarter, so far to 216, from total ROA ranking in the third quarter of 2013 at 4651.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2013)
IV. Quarter		 (Sep 30 2013)
III. Quarter		 (Jun 30 2013)
II. Quarter		 (Mar 31 2013)
I. Quarter		 (Dec 31 2012)
IV. Quarter
Y / Y Total Assets Change -7.04 % -65.71 % 17.76 % 83.05 % -39.35 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 68 -101 -110 -119 -141
Return On Assets (TTM) 36.75 % -54.37 % -48.66 % -55.51 % -75.71 %
CADX's Total Ranking # 216 # 4651 # 4541 # 4408 # 4439
Total Assets (TTM) in million 91 84 306 257 98
Seq. Total Assets Change 8.07 % -72.5 % 18.99 % 162.92 % -60.13 %
Seq. Net Income Change - - - - -

CADX's 5 Years Annual ROA >> Back to CADX Management Effectiveness >> Compare CADX ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 7
Sector # 37
Overall # 151

Return On Assets Statistics
High Average Low
75.25 %
-70.89 %
-113.78 %
(Dec 31 2013)   (Dec 31 2012)





Financial Statements
Cadence Pharmaceuticals Inc's Assets $ 91 million CADX's Balance sheet
Cadence Pharmaceuticals Inc's Income $ 88 million Quarterly CADX's Income Statement
CADX's Income by Division See CADX's Income by Division



Annual Return On Assets (Dec 31 2013)
FY 2013		 (Dec 31 2012)
FY 2012		 (Dec 31 2009)
FY 2011
FY
FY
Y / Y Total Assets Change -7.04 % -39.02 % - - -
Total Assets in million 91 98 160 0 0
Y / Y Net Income Change - - - - -
Net Income in million -24 -81 -45 0 0
Annual Return On Assets -26.75 % -82.9 % -28.4 % - -

CADX's 5 Years Annual ROA >> Back to CADX Management Effectiveness >> Compare CADX ROA to its Competitors



More Return On Assets Ratios
CADX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CADX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CADX's Competitors
Subscribers only: Roa for Cadence Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Assets for CADX's Customers

You may also want to know
CADX's Roi CADX's Inventory Turnover Ratio CADX's Growth Rates CADX's Dividend Comparisons
CADX's Profitability Ratios CADX's Asset Turnover Ratio CADX's Dividend Growth
CADX's Roe CADX's Valuation Ratios CADX's Financial Strength Ratios CADX's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2013, within Healthcare Sector ROA
Brainstorm Cell Therapeutics inc   100.57 %
Cyclo Therapeutics Inc   99.82 %
Savara Inc   95.48 %
Bluebird Bio Inc   93.86 %
Epizyme Inc.  85.66 %
Biocorrx Inc   79.56 %
Glucotrack Inc   76.46 %
Cadence Pharmaceuticals Inc  75.25 %
China Yct International Group, Inc.  67.04 %
Sorrento Therapeutics Inc   65.91 %
Oramed Pharmaceuticals Inc  62.54 %
Filana Therapeutics Inc   60.10 %
Arena Pharmaceuticals Inc   59.86 %
Mymetics Corporation  53.63 %
Portola Pharmaceuticals inc   53.06 %
Lightwave Logic Inc   49.42 %
Agios Pharmaceuticals Inc   42.54 %
Gentium S.p.a.  37.58 %
Insys Therapeutics, Inc.  36.82 %
Veru Inc   36.44 %
Nephros Inc   35.32 %
Insite Vision Inc  33.85 %
Ethema Health Corporation   33.83 %
Oncomed Pharmaceuticals Inc  32.48 %
Clearpoint Neuro Inc   29.74 %
Viskase Holdings inc   29.16 %
Camp4 Therapeutics Corporation  25.76 %
Psychemedics Corporation  25.60 %
Milestone Scientific Inc   24.75 %
Biospecifics Technologies Corp  24.69 %

Date modified: 2026-09-08T15:09:23+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.